Immunogenicity and protectivity of the peptide vaccine against SARS-CoV-2
- 作者: Ryzhikov A.B.1, Ryzhikov E.А.2, Bogryantseva M.P.1, Danilenko E.D.1, Imatdinov I.R.1, Nechaeva E.A.1, Pyankov O.V.1, Pyankova O.G.1, Susloparov I.M.1, Taranov O.S.1, Gudymo A.S.1, Danilchenko N.V.1, Sleptsova E.S.2, Bodnev S.A.1, Onkhonova G.S.1, Petrov V.N.1, Moiseeva A.A.1, Torzhkova P.Y.1, Pyankov S.A.1, Tregubchak T.V.1, Antonets D.V.1, Gavrilova E.V.1, Maksyutov R.A.1
-
隶属关系:
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
- Limited Liability Company “EpiVac”
- 期: 卷 76, 编号 1 (2021)
- 页面: 5-19
- 栏目: INFECTIOUS DISEASES: CURRENT ISSUES
- URL: https://ogarev-online.ru/vramn/article/view/125671
- DOI: https://doi.org/10.15690/vramn1528
- ID: 125671
如何引用文章
详细
Background. In 2020, the pandemic caused by novel coronavirus infection has become one of the most critical global health challenges during the past century. The lack of a vaccine, as the most effective way to control the novel infection, has prompted the development of a large number of preventive products by the scientific community. We have developed a candidate vaccine (EpiVacCorona) against novel coronavirus infection caused by SARS-CoV-2 that is based on chemically synthesized peptides conjugated to a carrier protein and adsorbed on aluminum hydroxide and studied the specific activity of the developed vaccine.
Aims — study of the immunogenicity and protectivity of the peptide candidate vaccine EpiVacCorona.
Methods. The work was performed using standard molecular biological, virological and histological methods.
Results. It was demonstrated that EpiVacCorona, when administered twice, spaced 14 days apart, to hamsters, ferrets, and non-human primates (african green monkeys, rhesus macaques) at a dose of 260 μg, which is equal to one inoculation dose for humans, induces virus-specific antibodies in 100% of the animals. Experiments in hamsters showed this vaccine to be associated with the dose-dependent immunogenicity. The vaccine was shown to accelerate the elimination of the virus from the upper respiratory tract in ferrets and prevent the development of pneumonia in hamsters and non-human primates following a respiratory challenge with novel coronavirus.
Conclusions. The results of a preclinical specific activity study indicate that the use of EpiVacCorona has the potential for human vaccination.
作者简介
Aleksandr Ryzhikov
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: ryzhik@vector.nsc.ru
ORCID iD: 0000-0002-7009-0748
SPIN 代码: 9282-2863
Cand. Sc. (Biology), Department Head
俄罗斯联邦, 630559, Koltsovo, Novosibirsk RegionEvgenii Ryzhikov
Limited Liability Company “EpiVac”
Email: e.a.ryzhikov@gmail.com
ORCID iD: 0000-0002-4233-7870
Director
俄罗斯联邦, Koltsovo, Novosibirsk RegionMarina Bogryantseva
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: bogryantseva@vector.nsc.ru
ORCID iD: 0000-0003-0467-5024
SPIN 代码: 5017-6279
Cand. Sc. (Biology), Department Head
俄罗斯联邦, Koltsovo, Novosibirsk RegionElena Danilenko
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: danilenko_ed@vector.nsc.ru
ORCID iD: 0000-0001-5026-1602
SPIN 代码: 1388-4127
Cand. Sc. (Biology), Director
俄罗斯联邦, Koltsovo, Novosibirsk RegionIlnaz Imatdinov
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: imatdinov_ir@vector.nsc.ru
ORCID iD: 0000-0002-6927-7580
SPIN 代码: 8174-1635
Cand. Sc. (Biology), Leading Researcher
俄罗斯联邦, Koltsovo, Novosibirsk RegionElena Nechaeva
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: nechaeva@vector.nsc.ru
ORCID iD: 0000-0002-6901-7738
SPIN 代码: 9270-8888
Cand. Sc. (Medicine), Deputy Director General
俄罗斯联邦, Koltsovo, Novosibirsk RegionOleg Pyankov
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: pyankov@vector.nsc.ru
ORCID iD: 0000-0003-3340-8750
SPIN 代码: 8622-9293
Cand. Sc. (Biology), Department Head
俄罗斯联邦, Koltsovo, Novosibirsk RegionOlga Pyankova
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: pyankova_og@vector.nsc.ru
SPIN 代码: 5872-2078
Leading Researcher
俄罗斯联邦, Koltsovo, Novosibirsk RegionIvan Susloparov
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: imsous@vector.nsc.ru
ORCID iD: 0000-0002-9718-7339
SPIN 代码: 8371-4785
Cand. Sc. (Biology), Senior Researcher
俄罗斯联邦, Koltsovo, Novosibirsk RegionOleg Taranov
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: taranov@vector.nsc.ru
ORCID iD: 0000-0002-6746-8092
SPIN 代码: 5894-6518
Department Head
俄罗斯联邦, Koltsovo, Novosibirsk RegionAndrei Gudymo
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: gudymo_as@vector.nsc.ru
ORCID iD: 0000-0001-6952-6412
SPIN 代码: 5274-0265
Junior Researcher
俄罗斯联邦, Koltsovo, Novosibirsk RegionNatalya Danilchenko
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: danilchenko_nv@vector.nsc.ru
ORCID iD: 0000-0003-2655-4629
SPIN 代码: 3041-1686
Junior Researcher
俄罗斯联邦, Koltsovo, Novosibirsk RegionEkaterina Sleptsova
Limited Liability Company “EpiVac”
Email: katyuss@yandex.ru
Head of the Quality Control Department
俄罗斯联邦, Koltsovo, Novosibirsk RegionSergei Bodnev
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: bodnev@vector.nsc.ru
ORCID iD: 0000-0003-0599-3817
SPIN 代码: 2219-2723
Cand. Sc. (Medicine), Leading Researcher
俄罗斯联邦, Koltsovo, Novosibirsk RegionGalina Onkhonova
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: onhonova_gs@vector.nsc.ru
ORCID iD: 0000-0002-1547-1708
SPIN 代码: 2017-8031
Junior Researcher
俄罗斯联邦, Koltsovo, Novosibirsk RegionVladimir Petrov
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: vnpetrov@vector.nsc.ru
ORCID iD: 0000-0002-3270-8412
Department Head
俄罗斯联邦, Koltsovo, Novosibirsk RegionAnastasiya Moiseeva
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: chalaya_aa@vector.nsc.ru
ORCID iD: 0000-0001-7048-2357
SPIN 代码: 9361-8776
Junior Researcher
俄罗斯联邦, Koltsovo, Novosibirsk RegionPolina Torzhkova
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: torzhkova_pyu@vector.nsc.ru
ORCID iD: 0000-0002-0387-1907
SPIN 代码: 8720-8129
Research Intern
俄罗斯联邦, Koltsovo, Novosibirsk RegionStepan Pyankov
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: pyankov_sa@vector.nsc.ru
ORCID iD: 0000-0002-6593-6614
SPIN 代码: 1344-4854
Leading Researcher
俄罗斯联邦, Koltsovo, Novosibirsk RegionTatyana Tregubchak
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
编辑信件的主要联系方式.
Email: tregubchak_tv@vector.nsc.ru
ORCID iD: 0000-0001-9608-2044
SPIN 代码: 1028-1981
Leading Researcher
俄罗斯联邦, Koltsovo, Novosibirsk RegionDenis Antonets
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: antonec@yandex.ru
ORCID iD: 0000-0002-1823-9701
SPIN 代码: 6825-8804
Cand. Sc. (Biology), Senior Researcher
俄罗斯联邦, Koltsovo, Novosibirsk RegionElena Gavrilova
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: gavrilova_ev@vector.nsc.ru
ORCID iD: 0000-0002-7118-5749
SPIN 代码: 4523-9695
Cand. Sc. (Biology), Deputy Director
俄罗斯联邦, Koltsovo, Novosibirsk RegionRinat Maksyutov
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being
Email: maksyutov_ra@vector.nsc.ru
ORCID iD: 0000-0003-1314-281X
SPIN 代码: 7332-2123
D.Sc. (Biology), General Director
俄罗斯联邦, Koltsovo, Novosibirsk Region参考
- Q&A: Influenza and COVID-19 — similarities and differences. World Health Organization. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-similarities-and-differences-covid-19-and-influenza
- Draft landscape of COVID-19 candidate vaccines.World Health Organization. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
- Wang QD, Zhang LF, Kuwahara K, et al. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infect Dis. 2016;2(5):361–376. doi: https://doi.org/10.1021/acsinfecdis.6b00006
- Song WF, Gui M, Wang XQ, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PloS Pathogens. 2018;14(8):e1007236. doi: https://doi.org/10.1371/journal.ppat.1007236
- GISAID Database. Available from: https://www.gisaid.org/
- Maksyutov AZ, Bachinskii AG, Bazhan SI, Ryzhikov EA. Design of safe AIDS vaccines based on search for local similarities between HIV-1 and human proteins. AIDS vaccines and related topics. Bourinbaiar AS, ed. Research Signpost, Kerala, India; 2004. P.47–62.
- Goncharova E, Ryzhikov E, Poryvaev V, et al. Intranasal immunization with inactivated tick-borne encephalitis virus and the antigenic peptide 89–119 protects mice against intraperitoneal challenge. Int J Med Microbiol. 2006;296(Suppl 40):195–201. doi: https://doi.org/10.1016/j.ijmm.2006.02.002
- Maksyutov AZ, Ryzhikov AB, Kolobov AA, Maksyutov ZA. Antigenic peptides. Patent WO 2004/031212;2004.
- Bjornson-Hooper ZB, Fragiadakis GK, Spitzer MH, et al. A comprehensive atlas of immunological differences between humans, mice and non-human primates. bioRxiv. 2019:574160. doi: https://doi.org/10.1101/574160
- Zaks L. Statistical estimation. (Theory and methods). Moscow: Statistika; 1976.
- Ashmarin IP, Vorob’yov AA. Statistical Methods in Microbiological Research. Leningrad: Medgiz; 1962.
- R v.4.0.2; R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: https://www.R-project.org
- Ni L, Ye F, Cheng M-L, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971–977.e3. doi: https://doi.org/10.1016/j.immuni.2020.04.023
- Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, Gavrilova EV, Danilenko ED, Imatdinov IR, Maksyutov RA, Nechaeva EA, Popova AYu, Pyankov OV, Pyankova OG, Suloparov IM. Peptide immunogens and vaccine composition against COVID-19 coronavirus infection using peptide immunogens. Patent RU 2738081. 2020.
- Azmi F, Ahmad Fuaad AA, Skwarczynski M, Toth I. Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum Vaccin Immunother. 2014;10(3):778–796. doi: https://doi.org/10.4161/hv.27332
- Tang F, Quan Y, Xin ZT, et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011;186(12):7264–7268. doi: https://doi.org/10.4049/jimmunol.0903490
- Ng OW, Chia A, Tan AT, et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016;34(17):2008–2014. doi: https://doi.org/10.1016/j.vaccine.2016.02.063
- Musicò A, Frigerio R, Mussida A, et al. SARS-CoV-2 Epitope Mapping on Microarrays Highlights Strong Immune-Response to N Protein Region. Vaccines (Basel). 2021;9(1):35. doi: https://doi.org/10.3390/vaccines9010035
- Shrock E, Fujimura E, Kula T, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020;370(6520):eabd4250. doi: https://doi.org/10.1126/science.abd4250
- Wang H, Wu X, Zhang X, et al. SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution. ACS Cent Sci. 2020;6(12):2238–2249. doi: https://doi.org/10.1021/acscentsci.0c00742
- Ferretti AP, Kula T, Wang Y, et al. Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity. 2020;53(5):1095–1107.e3. doi: https://doi.org/10.1016/j.immuni.2020.10.006
- He J, Huang JR, Zhang YL, Zhang J. SARS‐CoV‐2 nucleocapsid protein intranasal inoculation induces local and systemic T cell responses in mice. J Med Virol. 2021;93:1923–1925. doi: https://doi.org/10.1002/jmv.26769
- Ahlén G, Frelin L, Nikouyan N, et al. The SARS-CoV-2 N Protein Is a Good Component in a Vaccine. J Virol. 2020;94(18):e01279–20. doi: https://doi.org/10.1128/JVI.01279-20.
补充文件
